Takeda targets 2027 India launch for Qdenga dengue vaccine
Takeda plans to commercially launch its DCGI-approved Qdenga dengue vaccine in India in the first half of 2027, beginning with private channels before pursuing state and central procurement. The two-dose vaccine is approved for people aged 4-60.
What happened
Takeda Pharmaceutical · Takeda plans to commercially launch its DCGI-approved Qdenga dengue vaccine in India in the first half of 2027, initially through
Key facts
- Qdenga is approved for individuals aged 4-60
- Commercial launch targeted for first half of 2027
- India accounts for nearly one-third of the global dengue burden
- Reported dengue cases exceeded 121,000 in 2025, with 131 deaths
- Two-dose regimen administered three months apart
- 54-month data showed 84.1% efficacy against dengue-related hospitalisations
- Qdenga has approvals in more than 40 countries
Why this matters
Vaccine distributors, hospital chains and diagnostics players have partnership opportunities around Qdenga access, patient identification and immunisation-program support ahead of public-sector tenders.
What to watch
- DCGI labeling details, post-marketing requirements and any restrictions on age, prior dengue exposure or dosing intervals.
- Takeda's India price per dose, two-dose package price and announced private-provider footprint.
- Dengue incidence and outbreak severity during the 2026 and 2027 monsoon seasons.
- State government expressions of interest, pilot announcements, tenders or budget allocations for dengue vaccination.
- National Technical Advisory Group on Immunization discussions on dengue vaccine policy and cost-effectiveness.
- Competitor vaccine trial results, India licensing activity, local manufacturing plans or tender pricing.
- Evidence on dose-two completion rates, real-world effectiveness and safety in Indian recipients.
- Whether Qdenga obtains WHO-related procurement support or expanded global public-health endorsements.
- Build a private-channel launch network spanning hospital chains, pediatricians, infectious-disease specialists, diagnostic labs and corporate-health intermediaries.
- Create patient-completion infrastructure for the two-dose regimen, including digital reminders, provider incentives and bundled vaccination appointments.
- Generate India-specific disease-burden, health-economic, safety and effectiveness evidence to support state tender discussions and eventual central procurement.
- Develop tiered pricing, financing and access programs to expand beyond affluent urban consumers without undermining tender economics.
- Secure cold-chain capacity, predictable import/supply allocation and local pharmacovigilance operations ahead of the 2027 launch.
- Engage state health departments in high-burden regions on targeted pilot designs, outbreak-season preparedness and priority-population strategies.